Nuvalent Inc
NUVLHealthcare|Biotechnology|USA
$123.90
+0.06 (+0.05%)
Tangible Book
$14.89
Clinical Trials (6)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06765109 Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC | Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive | P3 | Recruiting | 450 | RCT, Single-blind | Neladalkib (NVL-655), Alectinib |
| NCT05118789 A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1) | Locally Advanced Solid Tumor, Metastatic Solid Tumor | P1P2 | Recruiting | 359 | Open-label | Zidesamtinib (NVL-520) |
| NCT05384626 A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) | Locally Advanced Solid Tumor, Metastatic Solid Tumor | P1P2 | Recruiting | 840 | Open-label | Neladalkib (NVL-655), Midazolam, Repaglinide, Itraconazole |
| NCT06521554 A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1) | Locally Advanced Solid Tumor, Metastatic Solid Tumor | P1 | Recruiting | 200 | Open-label | NVL-330 |
| NCT06797362 Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors | Non Small Cell Lung Cancer, ROS1-positive Non-Small Cell Lung Cancer (NSCLC) | AVAILABLE | — | — | NVL-520 | |
| NCT06834074 Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors | Non Small Cell Lung Cancer, ALK-positive Non-small Cell Lung Cancer (NSCLC) | AVAILABLE | — | — | NVL-655 |